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33 Metabolic responses to food influence cardiometabolic disease risk, but large-scale high-resolution 
 
34 studies are lacking. We recruited n=1,002 twins and unrelated healthy adults in the UK into the 
 
35 PREDICT1 study and assessed postprandial metabolic responses in a clinic setting and at home. We 
 
36 observed large inter-individual variability (population coefficient of variation [SD/mean]%) in 
 
37 postprandial blood triglyceride (103%), glucose (68%), and insulin (59%) responses to identical 
 
38 meals. Person-specific factors, such as the gut microbiome, had a greater influence ( 7.1% of 
 
39 variance) than meal macronutrients (3.6%) for postprandial lipemia, but not for postprandial 
 
40 glycemia (6.0% and 15.4% respectively); genetic variants had a modest impact on predictions (9.5% 
 
41 for glucose, 0.8% for triglyceride, 0.2% for c-peptide). Findings were independently validated in a US 
 
42 cohort (n=100). We developed a machine learning model that predicted both triglyceride (r=0.47) 
 
43 and glycemic (r=0.77) responses to food intake. These findings may be informative for developing 
 






47 Effective prevention strategies are required to reduce the immense global burden of nutrition- 
 
48 related non-communicable diseases (NCD)1. Nutritional research and the corresponding guidelines2-4 
 
49 focus on population averages. However, the high between-person variability in response to foods 
 
50 and weight-loss diets5 demands development of more personalized approaches. Empirically-based 
 
51 precision nutrition requires research using multi-dimensional, high-resolution time-series data from 
 
52 adequately powered studies6. The application of technologies to accurately and precisely quantify 
 
53 many postprandial (non-fasting) traits in large cohorts and in real-world settings is extending 
 




56 Although fasting blood assays are used in many clinical diagnoses, most people are predominantly in 
 
57 the postprandial state during waking hours. Postprandial lipid, glucose and insulin dyshomeostasis 
3  
58 are independent risk factors for NCDs and obesity7,8,9. Postprandial hyperglycemia raises risk of 
 
59 cardiovascular disease (CVD), coronary heart disease (CHD) 10 and cardiovascular mortality, even in 
 
60 individuals with normal fasting  glucose11,  and postprandial  triglyceride  is more  predictive  of CVD 
 
61 than fasting concentrations 12,13, highlighting the relevance of diet and its metabolic consequences in 
 




64 A person’s unique postprandial glycemic and lipiaemic responses are likely attributable their 
 
65 biological (e.g. microbiome and nuclear DNA variation) and lifestyle characteristics2,14, as 
 
66 demonstrated previously for specific meals5. While postprandial glycemic responses are important 
 
67 health determinants, glycemic control is just one part of a more complex metabolic equation 
 
68 involving triglyceride (the primary alternative energy substrate to glucose) and insulin (regulating 
 
69 glucose and triglyceride transport and metabolism)15. Thus, also characterizing postprandial 
 
70 regulation of lipids and identifying the factors responsible for individual variations could help 
 




73 The PREDICT 1 clinical trial (NCT03479866) was designed to quantify and predict individual variations 
 
74 in postprandial triglyceride, glucose and insulin responses to standardized meals. PREDICT 1 enrolled 
 
75 twins and unrelated adults from the UK in whom genetic, metabolic, microbiome composition, meal 
 
76 composition and meal context data were obtained to distinguish predictors of individual responses 
 




79 Our findings show wide variations in postprandial responses between people, even identical twins, 
 
80 attributable in large part to modifiable factors. We found that people who experience poor 
 
81 metabolic responses to a given meal are likely to respond poorly to other meals of the same 
 
82 macronutrient profile, and the overall correlation between postprandial glucose and triglyceride 
4  
83 responses is weak. The postprandial prediction models we have developed could help to optimize 
 








88 1002 healthy adults from the UK completed baseline clinic measurements consisting of postprandial 
 
89 metabolic responses (0-6h; blood triglyceride, glucose and insulin concentrations) to sequential 
 
90 mixed-nutrient dietary challenges. Findings were validated a US cohort of 100 healthy adults. 
 
91 Additional data was collected over the subsequent 13-day period at home, where postprandial 
 
92 responses to eight meals (seven in duplicate) of different macronutrient (fat, carbohydrate, protein 
 
93 and fiber) content were measured using continuous glucose monitors (CGM) and dried blood spot 
 
94 (DBS) analysis. The study design is described in detail in the Methods and Figure 1, the inclusion 
 
95 criteria and descriptive characteristics of study subjects are presented in Supplemental Table 1. 
 
96 Further information on the research design is available in the Life Sciences Reporting Summary 
 




99 Inter- and intra-individual variation in postprandial responses 
 
100 Inter-individual variability in postprandial responses was examined in a tightly controlled clinic 
 
101 setting following the sequential standardized test meal challenge after fasting (Figure 2a). The inter- 
 
102 individual patterns of response for each outcome was assessed using Levene’s test of variance. 
 
103 Heterogeneity across all postprandial time-points (fasting to 6-hrs) varied greatly for triglyceride 
 
104 (p=3.931e-11),  glucose  (p=2.91e-194)  and  insulin  (p=2.45e-17)  concentrations.  In  serum,  the 
 
105 population coefficient of variation was higher for postprandial triglyceride6hr-rise (103%) and 
 
106 glucoseiAUC0-2h (68%) compared with fasting values (50% and 10%, respectively). This was not true for 
 
107 insuliniAUC0-2h (59%) compared to fasting (69%; Figure 2a), suggesting that these measures of 
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of an individual’s metabolic tolerance than fasting values. 
 
111 A key assumption when developing personalized prediction algorithms is that an individual’s unique 
 
112 response to the same meal is reproducible. Much of the between-person phenotypic variability 
 
113 observed in studies examining response to diet interventions that include only a single test– 
 
114 response scenario could be a result of regression to the mean and other sources of error. Repeated- 
 
115 measures (multiple measures taken within individual at a single time-point and across multiple time 
 
116 points) can be used to partition error from true biological variability, thereby improving the precision 
 
117 of the estimate. Accordingly, we administered test meals of varying macronutrient composition in 
 
118 duplicate per participant, under similar conditions (see Methods and Supplemental Table 2 for 
 
119 details). We also used continual glucose monitors (CGMs), which provided sequential measures of 
 
120 blood glucose at 5 minute intervals during the study period. Intra-individual variability (repeatability) 
 
121 was assessed using intra-class correlation coefficients (ICC) for triglyceride, C-peptide (from DBS 
 
122 assays)  and  glucose  (from  CGM)  measurements.  The  ICCs  were:  triglyceride6h-rise=0.46  [95%  CI  0.37, 
 
123 0.54];  glucoseiAUC0-2h=0.74  [95%  CI  0.72,  0.75];  C-peptide2h-rise=0.62  [95%  CI  0.54,  0.69]  (Supplemental 
 





reflect the different assays used (DBS and CGM) (see Methods). 
 
127 Predicting individual postprandial responses within a population 
 
128 We assessed the overall extent to which input variables (Supplemental Table 3) predict personal 
 
129 postprandial responses (Figure 2b-d), initially using multivariable linear regression. Input variables 
 
130 include: i) baseline characteristics (age, sex, clinical biochemistry (lipid, glycaemic and other 
 
131 measures), anthropometry)); ii) genetics (single nucleotide polymorphisms (SNPs)); iii) gut 
 
132 microbiome features); iv) habitual diet (from Food Frequency Questionnaire (FFQ)); v) meal context 
 
133 (sleep, previous meals, physical activity, meal sequence and /or timing); vi) meal composition 
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134 (energy from carbohydrate, sugar, fat, protein and fiber). Postprandial glycemic responses were 
 
135 determined from serum and CGM measurements in the clinic and at home (from 7 standardized 
 
136 meals and 6,616 readings; see Methods). Postprandial C-peptide and triglyceride were determined 
 
137 (from two standardized meals) from serum and DBS assays collected during the clinic and home 
 
138 phases . We also tested the correlation between fasting and postprandial characteristics and found 
 
139 that the correlation between postprandial triglyceride, with regards to postprandial glucose and 
 
140 postprandial C-peptide measures was low (Figure 3a). 
 
141 Individual baseline characteristics. The proportions of trait variance explained by individual baseline 
 
142 characteristics are shown in Figures 2b, c and d for triglyceride 6h-rise, glucoseiAUC0-2h,and C-peptide1h- 
 
143 rise respectively (Supplemental Table 3). 
 
144 Genetic factors . The heritability of postprandial responses in the UK cohort was examined using 
 
145 classical twin methods (variance components analyses) to establish the upper bound of what might 
 
146 be predicted by directly measured genetic variation. Two-thirds of the cohort was recruited from the 
 
147 TwinsUK registry 16, of which 230 twin pairs (n=460; 183 MZ and 47 DZ) were studied for heritability. 
 
148 Additive genetic factors explained 30% of the variance in glucoseiAUC0-2h, whereas only 4% of the 
 
149 variance in triglyceride6h-rise and 9% of the variance in insulin2h-rise were explained in this way 
 
150 (Figure 3b). The estimated genetic variances in insulin1h-rise and C-peptide1h-rise were close to zero 
 
151 (Supplemental Table 4). 
 
152 SNP-based genetic factors. In a subgroup of participants who are part of the TwinsUK cohort and 
 
153 had genome wide genotyping previously measured with available GWAS data (n=241), we tested 
 
154 whether 32 SNPs derived from previous genome-wide scans of postprandial glucose, insulin or 
 
155 triglyceride concentrations 17-21 were also associated with the postprandial variables studied here. 
 
156 Several SNPs were significantly (p<0.05) associated with these variables (Figure 3c and 
 
157 Supplemental Table 4), but collectively explained only ~9% of observed variation in glucoseiAUC0-2h 
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158 (Figure 2c), and less than 1% of variation for postprandial triglyceride and postprandial C-peptide 
 
159 (Figure 2b and 2d). 
 
160 Gut microbiome (16S rRNA). We estimated the contribution of gut microbiome composition using 
 
161 relative bacterial taxonomic abundances and measures of community diversity and richness, derived 
 
162 from 16S rRNA high-throughput sequencing of baseline stool specimens (Supplemental Table 4). We 
 
163 found that without adjusting for any other individual characteristics the gut microbiome 
 
164 composition explained 7.5% of postprandial triglyceride6h-rise, 6.4% of postprandial glucoseiAUC0-2h and 
 
165 5.8% of postprandial C-peptide1h-rise. 
 
166 Meal composition, habitual diet and meal context. To determine the impact of the macronutrient 
 
167 composition of meals, we measured triglyceride6h-rise and C-peptide1h-rise for two standardized home 
 
168 phase meals of contrasting macronutrient compositions (for triglyceride, comparison of meals 1 and 
 
169 7: 85 vs 28g of carbohydrate and 50 vs 40 g of fat at breakfast, both followed by a lunch of 71g 
 
170 carbohydrate and 22g fat; for C-peptide, comparison of meal 2 and 3: 71 vs 41 g of carbohydrate and 
 
171 22 vs 35 g of fat; Supplement Table 2) in subsets of participants (n=712 and n=186, 
 
172 respectively). GlucoseiAUC0-2h was measured for seven standardized meals (comparison of meals 1, 2, 
 
173 4, 5, 6, 7 and 8: 28 - 95 g carbohydrate; 0 - 53 g fat) totalling 9,102 meals in 920 individuals. The 
 
174 proportions of variance explained by meal composition, habitual diet, and by meal context are 
 
175 shown for triglyceride6h-risein Figure 2b, for glucoseiAUC0-2hin Figure 2c, and for C-peptide1h-risein Figure 
 
176 2d.  A  multivariate  regression  model  (meals  1,  2,  4,  5,  6,  7  and  8)  revealed  that  the  GlucoseiAUC0-2h 
 





respectively, after adjustment for carbohydrate consumption. 
 
180 Machine learning model. To estimate the unbiased predictive utility of the factors analysed, we 
 
181 used a machine learning approach robust to overfitting22. Random Forest regression models23 were 
 
182 fitted using all the informative features (meal composition, habitual diet, meal context, 
 
183 anthropometry, genetics, microbiome, clinical and biochemical parameters) to predict triglyceride6h- 
8  
184 rise, glucoseiAUC0-2h and C-peptide1h-rise in the UK cohort dataset. The predicted values were compared 
 
185 with the observed values for each trait using Pearson correlation coefficients (r); these correlations 
 
186 were r=0.47, r=0.77 and r=0.30 for triglyceride6h-rise, glucoseiAUC0-2h and C-peptide1h-rise, respectively. 
 
187 Similar correlations were observed in the held-out validation set (US cohort) and the model predictions 
 
188 for triglyceride6h-rise and glucoseiAUC0-2h were r=0.42 and r=0.75, respectively, but much weaker for C- 
 
189 peptide1h-rise (r=0.14) (Figure 4). The features used to fit the models are reported in Supplemental 
 
190 Table 5. The repeatability and robustness of the machine-learning model is presented in the 
 
191 Extended Data Figure 4. 
 
192 Postprandial responses in relation to surrogate scores of clinical outcomes. We compared the 
 
193 extent to which fasting and postprandial concentrations for the different biomarkers could be used 
 
194 to predict impaired glucose tolerance (7.8-11.0 mmol/L 2 hours after an OGTT) and atherosclerotic 
 
195 cardiovascular disease (ASCVD) 10-yr risk score (Methods ) by comparing the area under the receiver 
 
196 operator characteristics (ROC-AUC) curves; Figure 5. We found that fasting triglyceride and 
 
197 triglyceride6h-rise contributed similarly to the ROC-AUC for ASCVD risk, and that including both was 
 
198 more informative than including only one of them (Figure 5a). We also found that, although 
 
199 postprandial glucose was not as informative as fasting glucose, adding glucoseiAUC0-2h to fasting 
 
200 glucose resulted in a slightly higher ROC-AUCs (0.72 vs 0.69) for ASCVD 10-yr risk. Fasting C-peptide 
 
201 and fasting glucose were as effective (ROC AUC= 0.69) as fasting triglyceride in ASCVD prediction, 
 
202 whereas postprandial C-peptide (ROC AUC= =0.63) and postprandial glucose were weaker (ROC 
 
203 AUC= 0.62) than postprandial triglyceride (ROC AUC= 0.71). Fasting and postprandial triglyceride 
 
204 concentrations were weakly predictive (ROC AUC= 0.55 and 0.59, respectively) of impaired glucose 
 
205 tolerance (IGT), whereas fasting and postprandial C-peptide were moderately predictive (ROC AUC= 
 
206 0.64 and 0.65 respectively), although with no added predictive value in combination. We did not 
 
207 include here the prediction of IGT using CGM glucose. This is because IGT is defined solely based on 
 
208 the blood glucose concentration at 2hrs during an OGTT, which is captured by the CGM glucose 
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dependent upon one another. Results were similar in the UK and US cohorts (Figure 5). 
 
212 Decoding individual responses 
 
213 Having investigated postprandial responses within the population, we then explored the responses 
 
214 at the individual level. We examined glycemic responses, as the granular CGM data collected during 
 
215 the at-home phase enabled us to assess real-world effects in detail, which was not possible for 
 
216 triglyceride or C-peptide. We investigated how much of an individual’s postprandial response is a 
 
217 attributable to a meal’s glycemic properties, compared with how the variation resulting from other 
 
218 modifiable factors such as meal timing, exercise and sleep. 
 
219 We first examined the contribution of the meal. Although it is a widely held notion that, for an 
 
220 individual, variations in meal composition are primarily responsible for the variation in responses to 
 
221 food and that ranking of meal responses should be the same for all people24-25, we explored whether 
 
222 meal-specific responses unique to the individual exists. We ranked the order of each participant’s 
 
223 glucoseiAUC0-2h  for every possible pair of standardized meals consumed  at home. We then determined 
 
224 how frequently these rankings differed for each participant. For most pairs of meals, the ranking was 
 
225 the same for all individuals (e.g. OGTT has a higher glucoseiAUC0-2h than high-fiber muffins in all 
 
226 participants, Figure 6a). However, for select pairs of meals, the ranking was reversed in up to 48% of 
 
227 participants, such as between the medium fat and carbohydrate at lunch vs high carbohydrate 
 
228 breakfast (350 of 727 participants) (meal 2 vs. meal 4; Supplemental Table 2). In 186 out of 498 
 
229 (37.3%) participants, discrepancies were also seen between the high fat and the high protein meals 
 
230 (meals 7 and 8). The distribution of how these meals were ranked for the participants of the 
 
231 PREDICT study is presented in Extended Data 2. 
 
232 We note that the reordering of meal rankings could have been the result of noise. We therefore 
 
233 used ANOVA to estimate the effect size for the different factors explaining glycemic response (Figure 
 
234 6b), including person-specific effects (effects that vary between people but not between meals). As 
10  
235 described in the Methods, we considered not only the effect of the meal macronutrient and energy 
 
236 content in the response (meal composition), but also considered how each individual responded on 
 
237 average to all their set meals relative to the population (individual glucose scaling), as well as the 
 
238 effect of the individual’s meal-specific response, the error attributable to the glucose measurement 
 
239 and other sources of variation (including modifiable sources of variation such as sleep, circadian 
 
240 rhythm and exercise). 
 
241 We found that, consistent with the linear models described earlier, the ANOVA models show that 
 
242 there are three meal-related factors explaining individual glycemic responses. Meal macronutrient 
 
243 composition alters iAUC by 16.73% (95%CI 15.37 - 18.92%), but the individual glucose scaling is 
 
244 larger, altering iAUC by roughly 18.74% (17.96% - 19.46%), while the individual’s meal-specific 
 
245 response is much smaller, affecting the final meal iAUC by 7.63% (6.11% - 8.96%). Other modifiable 
 
246 sources of variation not directly related to the meal composition, such as meal timing, exercise and 
 
247 sleep, contributed similar amounts of variance as the meal’s composition (Figures 6b and c). 
 
248 To investigate whether modifying the order in which meals are consumed and time of the day affect 
 
249 glycemic responses, we looked at participants eating an identical meal (meal 2) for breakfast and 
 
250 lunch. The average glycemic response for the same individuals was on average 2-fold higher (t- 
 
251 statistic = -35.7, 2721 d.f.; P< 0.001) when the meal was ingested for lunch (mean glucose 2h 
 
252 iAUC=14254 SD=6593) (4h following the metabolic challenge breakfast) than when ingested for 
 






256 Nutrition and health are intimately linked. Each day people make diet-related decisions that are 
 
257 influenced by perceived enjoyment and satiation, as well as health benefits and harm attributed to 
 
258 specific foods and beverages. Standard nutritional guidelines 2-4 are typically based on population 
 
259 averages. However, it is increasingly evident that one-size nutritional recommendations do not fit 
 
260 all, which is exemplified by the variable efficacy of tightly controlled lifestyle intervention trials26-29. 
11  
261 To address these challenges, we undertook a two-week interventional trial, including a tightly- 
 
262 controlled in-clinic day and a two-week at-home phase, where postprandial metabolic responses to 
 
263 a series of standardized meals were obtained in more than 1,000 healthy adults from the UK and 
 
264 USA. The primary aim was to derive algorithms that predict an individual’s postprandial metabolic 
 
265 responses to specific foods. The core outcomes were variations in blood concentrations of 
 
266 triglyceride, glucose and insulin (or C-peptide), as these biomarkers work in concert to affect 
 
267 cardiometabolic risk8,30. 
 
 
268 In many cases, we observed responses that contrast with those reported in traditional clinic-based 
 
269 studies, thereby reshaping conclusions about the key factors influencing responses to foods. For 
 
270 example, genetic influence was less than expected, especially for triglyceride, while modifiable 
 
271 factors like meal timing conveyed larger effects than anticipated. 
 
 
272 Meal composition has large effects on postprandial insulinemic and lipidemic response31Some small 
 
273 studies suggest that meals with high-fat and/or protein content elicit very different postprandial 
 
274 responses than lower-fat and/or protein meals with identical carbohydrate content (reviewed in 31). 
 
275 The type of fat in a meal also alters the lipemic response32. However, measuring postprandial 
 
276 triglyceride and C-peptide at-home in large cohorts is both logistically challenging and places a 
 
277 considerable burden on. Thus, for pragmatic reasons, only two pairs of meals (high fat and high 
 
278 carbohydrate, respectively) were used to calculate postprandial triglyceride and C-peptide responses 
 
279 and the difference in macronutrient content of these meals was low. This limited number of 
 
280 different meals and their  relatively similar macronutrient content might  explain why the  effects 
 
281 seen for postprandial triglyceride and C-peptide were lower than expected. 
 
 
282 In addition to fasting concentrations of triglyceride and glucose, we found that postprandial 
 
283 triglyceride and glucose concentrations were informative for IGT and CVD risk determination. 
 
284 However, postprandial C-peptide measurements provided no additional information over fasting 
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285 concentrations. We found that although postprandial triglyceride and glucose responses were highly 
 
286 variable between individuals, a person’s response to the same meals was often similar and therefore 
 
287 predictable. Any given individual generally responds comparably to different meals of the same 
 
288 macronutrient profile, with some people experiencing large postprandial excursions across most 
 
289 meals, whereas others consistently experience modest responses. This is important for 
 
290 individualized prediction and recommendations, as it suggests that once one has learned about  an 
 
291 individual’s postprandial response to specific foods, their response to other foods could be inferred. 
 
 
292 We show that a person’s glycemic response is the result not only of individual-specific glucose 
 
293 scaling, which determines whether a person is a high or low responder to all meals, but that there 
 
294 are also meal-specific responses unique to an individual. Possible explanations include individual 
 
295 genetic differences in the ability to digest high-starch meals33. Zeevi and co-workers 5 reported an 
 
296 example where one participant had an exaggerated glycemic response to a banana but not to a 
 
297 cookie, whereas the second participant had the opposite response. We assessed this phenomenon 
 
298 in our data and found that individual glucose scaling and meal-specific responses both exist, but 
 
299 individual meal-specific responses are generally much more effective than scaling. 
 
 
300 People differ greatly in their responses to diet interventions. The DIETFITS study, for example, 
 
301 randomised 609 people to either a healthy low fat or a healthy low carbohydrate diet for 12- 
 
302 months34. By study end, average weight loss was similar between groups (~5-6kg), but wide 
 
303 variations were seen within groups (-30kg to +10kg). Elsewhere, the Diabetes Prevention Program 
 
304 showed that although a standardized intensive lifestyle intervention focusing on changes in diet 
 
305 (tailored only to the energy requirements of the individual) lowered diabetes risk substantially28, its 
 
306 efficacy varied greatly across the study population 26,27, and was determined to some extent by 
 
307 genetic factors29. While response to diet interventions will depend partly on adherence, findings 
 
308 from the PREDICT trial and elsewhere35,36 suggest that even in highly-adherent participants, 
13  
309 substantial response variations exist, which might be predictable. In PREDICT, non-food-specific 
 
310 factors (e.g., meal timing, sleep, activity) were highly informative of these person-specific responses. 
 
 
311 Previous large-scale studies of postprandial responses have focused solely on glycemic outcomes 
 
312 because assessing postprandial triglyceride and insulin concentrations in free-living conditions is 
 
313 challenging 2,25. Here, we assessed glycemic responses with CGMs, but also assessed triglyceride and 
 
314 C-peptide concentrations during the at-home period of the study using a validated DBS method and 
 
315 support from a specifically designed mobile app (Methods).The low correlation between triglyceride 
 
316 and glucose suggests that prediction algorithms relying solely on glucose would be insufficient for 
 
317 the detection of dysregulated triglyceride responses. 
 
 
318 The prediction algorithms we developed are likely to have been strengthened by the use of 
 
319 randomized,  mixed meals,  containing combinations  of macronutrients reflective of those seen  in 
 
320 real-world settings, rather than supra-physiological lipid or carbohydrate challenges, as used in 
 
321 previous studies. 
 
 
322 In general, genetics, contrary to our expectations, was not a predominant determinant of these 
 
323 responses; we found that the heritable fraction (the trait variance explained by additive genetic 
 
324 factors) of C-peptide and/or insulin concentrations at 1 hr was very low (0.3%) and at 2 hrs remained 
 
325 low (9.1%). The heritable fractions for postprandial triglyceride (6hr rise) and glucose (2hr iAUC) 
 
326 responses were higher, but still modest (16% and 30%, respectively). Despite the wealth of publicly 
 
327 available SNP data (see: www.type2diabetesgenetics.org), there is no robust data for these specific 
 
328 postprandial traits, as almost all published GWAS of serological traits have focused on fasting values. 
 
329 Nevertheless, in exploratory analyses, we examined the predictive value of loci previously linked to 
 
330 post-challenge triglyceride, glucose or insulin concentrations 17-21 but found that the predictive utility 
 
331 of these variants was poor, particularly for triglyceride and C-peptide (Figure 3c). The modest 
 
332 heritability of postprandial traits means that even in an unrealistically optimistic scenario, where 
14  
333 most of this trait variance is explained by known DNA variants, it is unlikely that prediction 
 
334 algorithms using DNA variant data alone, which many direct-to-consumer nutrigenomics companies 
 
335 advocate, would succeed. 
 
 
336 The lack of a major genetic component to these traits highlights the likely involvement of modifiable 
 
337 environment exposures. Indeed, we found that meal composition and context (e.g. meal timing, 
 
338 exercise, sleep and circadian rhythm) were core determinants of postprandial metabolism. These 
 
339 predictions were strengthened using data on gut microbiome diversity. Using machine learning 
 
340 combining all relevant data, an individual’s postprandial triglyceride and glycemic responses could 
 
341 be meaningfully predicted, with similar results in the US validation cohort. For C-peptide, the 
 
342 prediction was much weaker in the validation cohort (r=0.30 UK, r=0.14 US), possibly reflecting the 
 
343 lower number of test meals relative to the number of input variables, which could adversely affect 
 
344 the reliability of the prediction37. The postprandial glycemic predictions were similar to those 
 





347 Despite having developed these prediction algorithms, there is scope for improvement, such as 
 
348 inclusion of a more diverse array of meal interventions and with more detailed assessments of 
 
349 contextual factors than in the current study. Technological advances could also help to improve 
 
350 predictions. For example, although glucose can be continuously assessed with CGMs, no 
 
351 commercially available devices suitable for free-living assessments of continuous insulin and 
 
352 triglyceride concentrations currently exist. Moreover, owing to the differences in tolerability and the 
 
353 lower limit of detectable responses of dietary carbohydrates compared with fats 38, our trial suggests 
 
354 that the prediction of postprandial glucose is methodologically superior to triglyceride responses 
 
355 (see Fig 2b-d). Difficulties in directly comparing changes in triglyceride and glucose were a limitation 
 
356 of our study. Continuous, accurate measures of these traits could substantially improve predictions 
 
357 owing to reductions in model error and the ability to study non-linear patterns of response, which 
15  
358 may be important. The inclusion of deep ‘-omics’ data may further enhance the predictive ability of 
 
359 these algorithms; for example, here we used microbiome data derived from 16S RNA sequencing, 
 
360 which, whilst proving valuable for prediction (explaining 6.4% and 7.5% of the variances for glucose 
 
361 and triglyceride responses, respectively), may prove even more informative if derived from higher- 
 
362 resolution metagenomic sequencing. The nutritional signatures detectable within the metabolome, 
 
363 both in blood39 and feces 40, suggest that including a larger metabolomics panel and quite probably 
 
364 other -omics data, e.g. meta-transcriptomics, transcriptomics or proteomics, in our algorithms would 
 
365 add costs but also enhance predictions. Using FFQs, we found that habitual diet explains a small 
 
366 proportion (<2%) of an individual’s postprandial responses. However, FFQs have well-known 
 
367 limitations,  and  other  objective  approaches  may  be  considerably  less  biased  and  error  prone27. 
 
368 Pairing this with short-term assessments, like the weighed dietary record included in the PREDICT 
 
369 study app, may help mitigate these limitations. More comprehensive challenge tests might also 
 
370 reveal new aspects of postprandial metabolism; here, we used a 6-hr meal tolerance test, as this was 
 
371 deemed the maximum duration that most participants were likely to accept. Data from longer 
 
372 duration challenge tests (up to 8hrs), for both glucose and triglyceride responses, may provide 
 
373 valuable information. 
 
 
374 For postprandial triglyceride and glucose responses, the prediction models derived in the UK cohort 
 
375 performed almost as well in the independent US validation cohort, which is reassuring given 
 
376 differences in environmental factors; nevertheless, both cohorts were comprised of younger healthy 
 
377 adults of European ancestry. Thus, the generalization of our findings would require validation in 
 
378 people of non-European ancestry, older adults, and in people with diseases that affect metabolism 
 
379 such as diabetes. The clinical implications of our predictions will require appropriately powered 
 
380 longitudinal studies. 
 
 
381 In conclusion, this is the most comprehensive assessment to date of metabolic responses to 
 
382 nutritional challenges in a rigorous intervention setting. We observed considerable inter-individual 
16  
383 differences in postprandial metabolic responses to the same meals, challenging the logic of 
 
384 standardized diet recommendations. These findings, in addition to the scalability of the assessment 
 
385 methods and the accuracy of the prediction algorithms described here, mean that, at least from a 
 
386 cardiometabolic health perspective, population-wide personalized nutrition has potential as a 
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(nmax=1,002) and an independent US-based validation cohort (nmax=100). 
 
439 Figure 2. Variation in postprandial responses. a. Inter-individual variation in triglyceride, glucose 
440 and insulin postprandial responses to the breakfast and lunch meal challenges in the clinic (n=1002). 
441 b. Determinants of triglyceride6h-rise measured from DBS (comparison of meals 1 and 7). c. 
442 Determinants of glucoseiAUC0-2h measured by CGM (comparison of 7 test meals; 1, 2, 4, 5, 6, 7 and 8). 
443 d. Determinants of C-peptide1h-rise measured from DBS as a proxy for insulin (comparison of meals 2 
444 and 3). Trait variations explained for each input variable are derived from separate (non-hierarchical) 
445 regression models. Values represent adjusted-R2 and error bars reflect 95% confidence intervals. 
446 Meal composition and Meal context adjusted-R2 values were derived from meal sample sizes as 
447 follows; triglyceride6h-rise, n=712; glucoseiAUC0-2h, n=9102; C-peptide1h-rise, n=186. All other determinant 
448 values were derived from meal sample sizes as follows; triglyceride6h-rise, n=920; glucoseiAUC0-2h, 
449 n=958; C-peptide1h-rise, n=960. TG= triglyceride, DBS= dried blood spots, CGM= continuous glucose 
450 monitor. * p<0.05, ** p<0.01, *** p<0.001 using multivariable linear regression. 
451 
 
452 Figure 3. Relationship of baseline values, genetic and microbiome factors to postprandial 
 
453 responses. a. Pearson correlations between baseline values and postprandial prediction measures of 
 
454 980 participants from the UK cohort. b. Heritability of postprandial responses (the ACE model was 
 
455 fitted on log-scaled postprandial responses for triglyceride, glucose, insulin and C-peptide) in 183 MZ 
 
456 and 47 DZ twin pairs. A; additive genetic component, C; shared environmental component, E; 
 
457 individual environmental component. c. SNP associations with postprandial measures focusing on 
 





sided chi-squared test). 
 
461 Figure 4 - Machine learning models fitted in to postprandial measures. a. Machine learning model 
 
462 for TG6h-rise in the UK cohort. b. Machine learning model for glucoseiAUC0-2h in the UK cohort. c. 
 
463 Machine learning model for C-peptide1h-rise postprandial responses in the UK cohort. The machine 
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464 learning models in the US validation cohort are shown in Figures 4 d-f. The relationship between 
 
465 variables is expressed as Pearson’s correlation coefficient (r) and denoted with a regression line; n 
 
466 represents participant number; the features used to predict each value are the same as those listed in 
 
467 the linear models in Figure 2b-d. 
 
468 Figure 5. Associations between fasting and postprandial values for TG, C-peptide and glucose 
 
469 concentrations with clinical measures in the UK cohort. Receiver operator characteristics curves 
 
470 illustrating the predictive utility of fasting and postprandial TG, glucose and C-peptide measures to 
 
471 discriminate the bottom 70% from the top 30% of the cohort (cut-off ASCVD 10 year risk of 0.0183) 
 
472 for a. atherosclerotic cardiovascular disease (ASCVD) 10-year risk n=951 independent samples from 
 
473 the UK and b. impaired glucose tolerance (IGT) n= 826 independent samples from the UK. The same 
 
474 analyses were performed in the US cohort (n=92 independent samples) resulting in ROC AUC (95%CI) 
 
475 values for ASCVD 10 year risk of: C-peptide fasting AUC=0.68 (0.56-0.80), postprandial AUC=0.66 
 
476 (0.54-0.77), both AUC=0.69 (0.58-0.81); TG fasting AUC =0.73(0.63-0.84), postprandial AUC =0.75 
 
477 (0.65-0.85), both AUC = 0.77 (0.67-0.88); and glucose fasting AUC= 0.74-(0.63-0.85), postprandial 
 
478 AUC = 0.64 (0.52-0.76), both AUC = 0.76 (0.64-0.85). For impaired glucose tolerance values were: C- 
 
479 peptide fasting AUC = 0.66 (0.53-0.80), postprandial AUC = 0.59 (0.46-0.72), both AUC = 0.67 (0.54- 
 
480 0.80); and Triglyceride fasting AUC = 0.66 (0.53-0.80), postprandial AUC = 0.59 (0.46-0.72), both 
 
481 AUC = 0.61 (0.54-0.80). 
 
482 Figure 6. Person-specific diversity in postprandial response. a. Proportion of times in the PREDICT 1 
 
483 study that the ranking of the glycemic response (glucoseiAUC0-2h) to pairs of set meals was altered 
 
484 (n=828, UK cohort). b. Effect size for factors explaining glycemic response. The different sources of 
 
485 variation were estimated using ANOVA, as described in Supplemental Table 3. The x-axis can be 
 
486 approximately interpreted as percent increase (or decrease) in iAUC attributable to the model 
 
487 parameters (n=483 individuals) c. Time of day effects. (n=920, UK cohort). Boxes show quartiles (25th, 
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592 Study population, study design, recruitment criteria, meal challenges and Zoe app. 
 
593 Study population 
 
594 The PREDICT 1 study (Personalised Responses to DIetary Composition Trial) was a multinational 
 
595 study conducted between 5th June 2018 and 8th May 2019. The primary cohort was recruited at St. 
 
596 Thomas’ Hospital in London, UK and a validation cohort (that underwent the same profiling as in the 
 
597 UK) assessed at Massachusetts General Hospital (MGH) in Boston, Massachusetts as described in the 
 
598 detail in the protocol 41. In the UK, participants (target enrolment = 1,000) were recruited from the 
 
599 TwinsUK cohort, an ongoing research cohort described elsewhere16 and online advertising (Extended 
 
600 Data Figure 1a). In the US, participants (target enrolment = 100) were recruited through online 
 
601 advertising, research participant databases and Rally for Research (https://rally.partners.org/), an 
 
602 online recruiting portal for research trials (Extended Data Figure 1b). Ethical approval for the study 
 
603 was obtained in the UK from the Research Ethics Committee and Integrated Research Application 
 
604 System (IRAS 236407) and in the US from the Institutional Review Board (Partners Healthcare IRB 
 
605 2018P002078). The trial was registered on ClinicalTrials.gov (registration number: NCT03479866), as 
 
606 part of the registration for the PREDICT Programme of research, which also includes 2 other study 
 





609 Study participants were healthy individuals aged between 18-65 years and able to provide written 
 
610 informed consent. Criteria used to assess eligibility are listed in Extended Data Table 1. Exclusion 
 
611 criteria included; ongoing inflammatory disease; cancer in the last three years (excluding skin 
 
612 cancer); long term gastrointestinal disorders including IBD or Coeliac disease (gluten allergy), but not 
 
613 including IBS; taking the following daily medications: immunosuppressants, antibiotics within the 
 
614 last three months; capillary glucose level of >12mmol/L (or 216 mg/dL), or Type I diabetes mellitus, 
24  
615 or taking medications for type II diabetes mellitus; currently suffering from acute clinically diagnosed 
 
616 depression; heart attack (myocardial infarction) or stroke in the last 6 months; pregnant; vegan, 
 
617 suffering from an eating disorder or unwilling to take foods that are part of the study. 
 
 
618 Study design 
619 1,002 generally healthy adults from the United Kingdom (UK) (non-twins, and identical 
 
620 [monozygotic; MZ] and non-identical [dizygotic; DZ] twins) and 100 healthy adults from the United 
 
621 States (US) (non-twins; validation cohort) were enrolled and completed baseline clinic 
 
622 measurements. Key outcomes include postprandial metabolic responses (0-6h; blood triglyceride, 
 
623 glucose and insulin concentrations) to sequential mixed-nutrient dietary challenges (containing 86g 
 
624 carbohydrate and 53g fat at 0h; 71g carbohydrate and 22g fat at 4h) administered in a tightly 
 
625 controlled clinic setting on day 1 (Figure 1). A second set of outcomes were assessed over the 
 
626 subsequent 13-days at home. Lipemic and C-peptide responses (as a surrogate for insulin) to two 
 
627 standard meals differing in fat and carbohydrate composition were assessed at home using dried 
 
628 blood spot (DBS) assays collected at three postprandial time-points. Glycemic responses to eight 
 
629 meals (seven in duplicate) of different macronutrient (fat, carbohydrate, protein and fiber) content 
 
630 were assessed using continuous glucose monitors (CGM). In addition, participants wore physical 
 




633 We selected specific timepoints and increments for triglyceride, glucose, insulin and C-peptide to 
 
634 reflect the different pathophysiological processes for each measure. To monitor compliance, all test 
 
635 meals consumed by participants were logged in the Zoe app (with an accompanying picture) and 
 
636 reviewed in real time by the study nutritionists. Only test meals that were consumed according to 
 
637 the standardized meal protocol were included in the analysis. 
 
638 Baseline clinic visit (Day 1): Participants in the UK were mailed a pre-visit study pack with a stool 
 
639 collection kit and a health and lifestyle (amended Twins Research health and lifestyle questionnaire 
 
640 42and food frequency questionnaire (European Prospective Investigation into Cancer and Nutrition 
25  
641 (EPIC) Food-Frequency Questionnaire (FFQ)43). In the US, minor modifications were made to the 
 
642 health and lifestyle questionnaires to conform to a US population and the Harvard Semi-quantitative 
 
643 FFQ, a validated US instrument, was substituted for the EPIC FFQ. Stool collection and 
 
644 questionnaires were completed at home and returned to study staff at the baseline visit. 
 
645 Participants were asked to refrain from exercise and to limit fat, fiber and alcohol intake for 24 hours 
 
646 beforehand and to abstain from caffeine from 6pm the night before the baseline visit. Participants 
 
647 arrived at 8:30am for their visit, having fasted from 9pm the night before, and were cannulated in 
 
648 the forearm (antecubital vein) to collect a fasted blood sample, before being fitted with wearable 
 
649 devices (continuous glucose monitor (CGM; Freestyle Libre Pro, Abbott, Abbott Park, IL, US) and 
 
650 wrist-based triaxial accelerometer (AX3, Axivity, Newcastle, UK)). Heart rate and blood pressure 
 
651 were measured using an automated blood pressure monitor while fasted (in triplicate, with mean of 
 
652 second and third measurements recorded). Participant weight, height, hip and waist circumference 
 
653 were measured using standard clinical techniques. Fasting blood glucose level was checked using 
 
654 HemoCue Glucose 201 + System (Radiometer, Crawley, UK) or Stat Strip (Nova Biomedical, Waltham, 
 
655 MA, US) in the UK and US, respectively. 
 
656 Following the baseline blood draw, participants consumed a breakfast (muffins and milkshake at 0 
 
657 min) and lunch (muffins at 240 min) test meal (Supplemental Table 2), each to be consumed within 
 
658 10 minutes. Additional venous blood was collected via cannula at 15, 30, 60, 120, 180, 240, 270, 300 
 
659 and 360 minutes. Participants had access to water to sip throughout the visit. Between blood 
 
660 sampling, participants were trained in how to complete the study at home, including when and how 
 





their baseline visit, participants received all the components necessary to complete the home-phase. 
 
664 Home-phase (Days 2-14): During the study home-phase, participants consumed multiple 
 
665 standardised test meals for breakfast and lunch over a 9-11-day period, differing in macronutrient 
 
666 composition (carbohydrate, fat, protein and fiber) while wearing the CGM and accelerometer. 
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667 Participants recorded all of their dietary intake and exercise on the Zoe study app throughout the 
 
668 study. DBS tests were completed on 4 days before and after test meals, as outlined in the online 
 





devices to study staff via standard mail. 
 
 
672 Test meal preparation, nutrient composition, timings and standardised participant test meal 
673 instructions 
674 Upon completing their baseline visit, participants received a home-phase meal pack containing test 
 
675 meal components (nutrient composition; Supplemental Table 2) which they consumed according to 
 
676 standardised instructions for breakfast and, on some days, lunch. Test meals consisted of either an 
 
677 oral glucose tolerance test (OGTT; on 2 days) or muffins, which were consumed on their own or 
 
678 paired with chocolate milk, protein shake, or commercial fiber bars and ordered according to one of 
 
679 3 protocol groups described in Supplemental Table 2. Meal order for the 3 protocol groups was 
 







683 Participants were instructed to fast for a minimum of 8 hours prior to consuming a test breakfast 
 
684 meal, and to fast for 3 or 4 hours after meal consumption (depending on test meal; in protocol 1, 
 
685 fasting period was 3 hours for Meal 5 and 4 hours for all other meals; in protocols 2 and 3, the 
 
686 fasting period was 3 hours for all breakfast meals, excluding combinations of breakfast and lunch, 
 
687 where fasting periods were 4 and 2 hours, respectively). They were advised to limit exercise and 
 
688 drink only plain, still water during fasting periods. When fasting was completed, participants could 
 
689 eat, drink and exercise as they liked for the rest of the day. Participants were asked to consume all 
 
690 muffin-based meals within 10 minutes and the OGTT within 5 minutes and to notify study staff if this 
 
691 was not achieved, in which case the data was excluded from analysis. If the participant chose to 
 
692 accompany their home-phase muffin-based test meals with a tea or coffee (with up to 40ml of 0.1% 
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693 fat cow’s milk, but no sugar or sweeteners), they were instructed to consume this drink consistently, 
 
694 in the  same  strength  and amount, alongside  all  muffin-based  test meals  throughout  the study. 
 





and to avoid physical activity during the 3-hour fasting period that followed it. 
 
698 Test meals and any dietary intake consumed within fasting periods, including accompanying drinks, 
 
699 were recorded in the Zoe app by participants with the exact time at consumption and ingredient 
 





completed according to instructions were included in analysis. 
 
703 Test meals were prepared and packaged in the Dietetics Kitchen (Department of Nutritional 
 
704 Sciences, King’s College London, London, UK) using standard ingredients; plain flour, sugar, baking 
 
705 powder, vanilla essence, milk, egg, salt, high-oleic sunflower oil, whey protein powder, chocolate 
 
706 milkshake powder (Nesquik, Nestle, Gatwick, UK), and commercially available fiber bars (Chocolate 
 
707 Fudge Brownie, Fiber One, General Mills, MN, US; Goodness Bar Apple & Walnut, The Food Doctor, 
 
708 Hessle, UK). Test meals were shipped frozen, under temperature controlled conditions, to the US to 
 
709 limit variability of the intervention. Participants were instructed to freeze their muffins at home and 
 
710 defrost each set of muffins in the fridge the night before consuming them. Test meal drinks were 
 
711 prepared by the participant at home by mixing pre-portioned powder sachets with long-life milk 
 
712 provided (Meal 1, 220ml 0.1% fat milk; Meal 8, 200ml 1.6% fat milk). Powder sachets and fiber bars 
 
713 were  stored  at  room  temperature  until  consumption.  The  OGTT  (Meal  5)  consisted  of  a pre- 
 
714 portioned powdered glucose sachet which participants mixed with 300ml water in the UK. In the US 
 







718 Zoe study app and dietary assessment methodology 
719 The Zoe app was developed to support the PREDICT 1 study by serving as an electronic notebook of 
 
720 study tasks, a tool for recording all dietary intake and a portal for communication with study staff. 
 
721 The app sent participants notifications and reminders to complete tasks at certain time-points, such 
 
722 as when their test lunch meals and DBS were due, and asked participants to report their hunger and 
 
723 alertness levels on visual analogue scales truncated from Flint et al 44. Participants were asked to log 
 
724 in the app any exercise which would not be well captured by a wrist-affixed accelerometer, such as 
 
725 cycling. Participants logged their full dietary intake using the app over the 14-day study period, 
 
726 including all standardized test meals and free-living foods, beverages (including water) and 
 
727 medications. Data logged into the app was uploaded onto a digital dashboard in real time and 
 
728 reviewed and assessed for logging accuracy and study guideline compliance by study staff. 
 
729 `Study staff trained all participants at their baseline clinic visit on how to accurately weigh and 
 
730 record dietary intake through the Zoe study app, using photographs, product barcodes, product- 
 
731 specific portion sizes, and digital scales. Study nutritionists also reviewed food logging data by 
 
732 comparing the photographs uploaded by subjects with the items they logged on the app. Any 
 





phone while the participant was on the study. 
 
736 Protocol versions and amendments 
 
737 Protocol amendments for the PREDICT study, post-commencement of the study and participant 
 
738 enrolment, are as follows: The first amendment (approved by UK IRAS 1st August 2018) allowed 
 
739 additional test meals to be included in the home-phase and participants’ logging of gut transit 
 
740 time by using a Metabolic Challenge Breakfast (Meal 1) on the clinic day dyed blue with food 
 
741 coloring. The  DBS  protocol was also  changed according to  physiological peaks  in  biomarkers 
 
742 (triglyceride or  C-peptide). Starting on  28  Aug  2018, triglyceride was measured  on  Days 2-3 at 
 
743 fasting, 300 and 360 minutes post-prandially, while C-peptide was quantified on Days 4-5 at 
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744 fasting, 30 and 120 minutes post-prandially as described for Protocol Group 2. A second saliva 
 
745 sample collection was also added on the clinic day, at 30 minutes after the metabolic challenge 
 
746 breakfast, to measure salivary amylase production post prandially and provide a comparison to 
 
747 fasted amylase levels. The second amendment (approved by UK IRAS 2nd September 2018) was 
 
748 a change in the lower BMI limit for eligibility to 16.5kg/m2 (originally 20 kg/m2). Minor meal 
 
749 changes were made, not requiring ethical approval, which resulted in Protocol Group 3 
 
750 (implemented in January 2019). In the US, on 3 January 2019, the IRB approved an amendment 
 
751 (PREDICT-US v2.0) to address meal changes introduced in the UK for Group 3 and to allow the 
 









755 Outcome variables and sample collection, handling and analysis 
 
756 Dried blood spot collection, method validation and analysis. 
757 Dried blood spot collection: Triglyceride and C-peptide were quantified from DBS tests completed by 
 
758 participants at the baseline visit (at fasted baseline and 300 minutes post-breakfast; for method 
 
759 validation) and on the first 4 days of the home-phase while consuming test meals (test timings and 
 
760 associated meals are outlined in the online protocol 41). 
761 
762 The Zoe app sent participants reminders to complete their DBS tests at due times, which participants 
 
763 then logged in the app by recording the time at testing and a photo of the completed card for quality 
 
764 assessment by study staff. Test cards not meeting the quality protocol (multiple small spots or 
 
765 inadequate coverage) were not included in analysis. Test cards were stored in aluminium sachets 
 
766 with desiccant once completed and placed in the fridge at the end of the study day or until 
 
767 participants mailed them back to the study site. DBS cards were then frozen (-80 °C) and shipped for 
 




770 Dried blood spot method validation: DBS C-peptide and triglyceride concentrations were validated 
 
771 during PREDICT, against venous serum concentrations collected during the baseline clinic visit at 0 
 





high; for triglyceride (1,772 pairs) Pearson’s r=0.94; for C-peptide (1,679 pairs) Pearson’s r=0.91. 
 
775 Quantification of total triglyceride from DBS: From the DBS sample, 2 punches were taken and 
 
776 transferred into a HPLC vial and lipids extracted with methanol at 600 rpm and 25 °C for 3 hours. The 
 
777 resulting extract was processed with a triglyceride kit (FUJIFILM Wako Chemicals GmbH, Neuss, 
 
778 Germany) at 600 rpm and 37 °C for 2.5 hours and the reaction products were subsequently analyzed 
 
779 by HPLC-UV. HPLC was performed with a HP 1260/1290 infinity liquid chromatograph (Agilent 
 
780 Technologies, Palo Alto, CA, US) using UV detection. The analyte was separated from matrix 
 
781 components on a 4.6 mm x 100 mm reversed phase column at 40 °C. A one-point calibration curve 
 





method is linear from 0.5-6 mmol/L with a quantification limit of 0.3 mmol/L. 
 
785 Quantification of C-peptide from DBS: C-peptide in DBS were assayed using a Mercodia solid phase 
 
786 two-site enzyme immunoassay (ELISA; Mercodia AB, Uppsala, Sweden). Three spots were punched 
 
787 into the kit plate with anti-C-peptide antibodies bound to the well. Assay buffers were added and C- 
 
788 peptide extracted from the spots at 4 °C. After washing, peroxidase-conjugated anti-C-peptide 
 
789 antibodies were added and after the second incubation and a washing step, the bound conjugate 
 
790 was detected by reaction with 3,3`,5,5`-tetramethylbenzidine (TMB). The reaction was stopped by 
 
791 adding acid to give a colorimetric endpoint that was read spectrophotometrically at 450 nm. 
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792 Stool sample collection, method validation and microbial analysis 
793 Stool sample collection: Participants collected a stool sample at home prior to their clinical visit. 
 
794 Samples were collected using the EasySampler collection kit (ALPCO, NH, US) into fecal collection 
 
795 tubes containing DNA/RNA Shield buffer (Zymo Research, CA, US). Upon receipt in the laboratory, 
 
796 samples were homogenised, aliquoted and stored at -80 °C in Qiagen PowerBeads 1.5 mL tubes 
 
797 (Qiagen, Germany). The sample collection procedure was tested and validated internally comparing 
 
798 different storage conditions (fresh, frozen, buffer), different DNA extraction kits (PowerSoilPro, 
 







802 Microbiome 16S rRNA gene sequencing and analysis: The DNA was isolated by QIAGEN Genomic 
 
803 Services using DNeasy® 96 PowerSoil® Pro. Optical density measurement was done using 
 
804 Spectrophotometer Quantification (Tecan Infinite 200). The V4 hyper-variable region of the 16S 
 
805 rRNA gene was then amplified at Genomescan, Leiden, Netherlands. Libraries were sequenced for 
 
806 300 bp paired-end reads using the Illumina NovaSeq6000 platform. In total, 9.6 Pbp were generated 
 
807 and raw reads were rarefied to 360k reads per sample. Rarefied reads were analyzed using the 
 
808 DADA2 pipeline 45. Quality control of the reads was performed using the "filterAndTrim" function 
 
809 from  the  DADA2  package  truncating  eight  nucleotides  from  each  read  to  remove  barcodes, 
 
810 discarding all reads with quality less than 20, discarding all reads with at least one N, and removing 
 
811 the phiX Illumina spike-in. Only paired-end reads with at least 120 bp and with an expected DADA2 
 
812 error less than 4 were retained for downstream analyses. Error rates were inferred from the cleaned 
 
813 set of reads ("learnErrors" function) and used in the DADA2 algorithm ("mergePairs" function) for 
 
814 merging the reads, after dereplication ("derepFastq" function). Merged reads were further 
 
815 processed retaining only reads within 280 and 290 bp, representing the majority of the distribution 
 
816 of the lengths. Reads were further processed to remove chimeras using the "removeBimeraDenovo" 
 
817 function with a consensus method. Finally, taxonomy was assigned using the SILVA database 
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818 (version 132) using the "assignTaxonomy" function and requiring a minimum bootstrap value of 80 
 
819 obtaining a table of relative abundances of operational taxonomic units (OTUs). To address the issue 
 
820 of compositionality in the microbiome data set46 the relative abundance values were normalized 
 
821 using the (arcsin-sqrt) transformation as described in 47. Measures of alpha diversity were computed 
 





16S abundance data are presented in Supplemental Table 4. 
 
 
825 Venous blood sample collection 
826 Participants came into the clinical research facilities at 8:30am and were cannulated in the forearm 
 
827 antecubital vein. Venous blood was collected at 0 minutes (prior to a test breakfast) and at 9 time- 
 
828 points postprandially (15, 30, 60, 120, 180, 240, 270, 300, and 360 minutes). Plasma glucose was 
 
829 analyzed from blood samples collected into fluoride oxalate tubes and centrifuged at 1900 g for 10 
 
830 min at 4 °C. Serum C-peptide, insulin, triglyceride, fasting lipid profile, thyroid stimulating hormone, 
 
831 alanine aminotransferase, and liver function panel were analyzed from blood samples collected into 
 
832 gel separator serum tubes and allowed to stand at room temperature before centrifuging at 1900 g 
 
833 for 10 min at 4 °C. Samples were aliquoted and stored at -80 °C. Blood, for complete blood count 
 








837 Serum biomarkers 
838 In the UK, insulin, glucose, triglyceride and C-peptide analysis was conducted by Affinity Biomarkers 
 
839 Labs (London, UK). Glucose and triglyceride analyses were conducted on a Siemens ADVIA 1800 
 
840 using Siemens assay kits (Siemens Healthcare Diagnostics Ltd, Surrey, UK). Triglyceride was analyzed 
 
841 using the ADVIA chemistry triglyceride method based on the Fossati three-step enzymatic reaction 
 
842 with a Trinder endpoint. Glucose was analyzed using the ADVIA chemistry glucose oxidase (GLUO) 
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843 method (based on the modified method of Keston). C-peptide and insulin were analyzed using the 
 
844 Siemens ADVIA Centaur XP systems using a two-site sandwich immunoassay. Complete blood count 
 
845 (CBC) was measured by Viapath (London, UK) for the UK cohort using standard automated clinical 
 
846 chemistry techniques. The inter-assay coefficient of variation for PREDICT samples analyzed by 
 
847 Affinity were: insulin 3.4%, C-peptide 7.9%, triglyceride 3.7%, and glucose 2.6%. 
 
848 In the US, CBC was established using fresh blood samples in the MGH Core Laboratory. Hb1AC tests 
 
849 were performed by the MGH Diabetes A1c lab. Glucose, insulin, triglyceride, and C-peptide were 
 




852 Upon completion of the US study, frozen serum and plasma samples were sent from the US to the 
 
853 UK and the entire cohort had liver function panel, full lipids (TC, HDL-C LDL-C and triglyceride), 
 
854 thyroid stimulating hormone and alanine aminotransferase measurements performed by Affinity 
 
855 Biomarkers Labs. Details described elsewhere 48. 
856 
 
857 Glucose using continuous glucose monitoring 
858 Interstitial glucose was measured every 15 minutes using Freestyle Libre Pro continuous glucose 
 
859 monitors (Abbott, Abbott Park, IL, US). Monitors were fitted by trained nurses on the upper, non- 
 
860 dominant arm at participants’ baseline visit and covered with Opsite Flexifix adhesive film (Smith & 
 
861 Nephew Medical Ltd, Hull, England) for improved durability, and worn for the entire study duration 
 
862 (14 days). Data collected 12 hours and onwards after activating the device was used for analysis. For 
 
863 a subgroup of participants (n=377), we fitted two monitors on their arms and calculated the 
 





standardized meals (Extended Data Figure 2b). 
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).0-6h,          max, 
867 Time points for analyses: 
868 Glucose: The 2-hour glucose iAUC was used for both clinic and at-home analyses. 
 
869 Insulin and C-peptide: C-peptide was measured at home as a surrogate for insulin secretion, 
 
870 because the reliability of C-peptide measured from DBS is higher than that of insulin (see49 ) and C- 
 
871 peptide remains stable on paper filters for up to 6 months 49. C-peptide was measured at 60 minutes 
 
872 postprandially to coincide with the peak in C-peptide seen in healthy individuals in clinic, and again 
 
873 at 120 minutes to coincide with the strong decline in insulin level (Extended Data Figure 2c). 
 
874 However, because previous genetic studies have tested the heritability of postprandial insulin at 120 
 
875 minutes, this time point was included for our own heritability analyses (Figures 2b-c). All other 
 
876 analyses refer to the 1-hour rise for C-peptide. 
877 
878 Triglyceride: The rise in triglyceride at 6 hours postprandially (triglyceride6h-rise) was selected to 
 
879 represent postprandial lipemic response from serum collected at clinic and home-based DBS tests. 
 
880 This is a measure of lipemia most closely correlated with atherogenic lipoproteins compared to 




883 Activity and sleep 
884 Energy expenditure was measured using a triaxial accelerometer (AX3, Axivity, UK) fitted by nurses 
 
885 at the baseline visit on the non-dominant wrist and worn for the duration of the study (except 
 
886 during water-based activities, including showers and swimming). Accelerometers were programmed 
 
887 to measure acceleration at 50 Hz with a dynamic range of ±8 g (where g refers to local gravitational 
 
888 force equal to 9.8 m/s2). Non-wear periods were defined as windows of at least 1 hour with less than 
 
889 13mg for at least 2 out of 3 axes, or where 2 out of 3 axes measured less than 50mg. Windows of 
 




893 Whole genome genotyping was available for 241 individuals from the UK cohort from previous 
 
894 TwinsUK studies. Genotyping was performed with the Illumina Infinium HumanHap610. Normalised 
 
895 GWAS intensity data were pooled and genotypes called on the basis of the Illuminus algorithm. No 
 
896 calls were assigned if the most likely call was less than a posterior probability of 0.95. Validation of 
 
897 pooling was done by visual inspection of 100 random, shared SNPs for overt batch effects (none 
 
898 were  observed).  SNPs  that  had  a  low  call  rate  (≤90%),  Hardy-Weinberg  p  values  <10−6     and  minor 
 
899 allele frequencies <1% were excluded, and samples with call rates <95% were removed. Genotype 
 
900 imputations were performed to increase the coverage. Imputation of genotypes for all polymorphic 
 
901 SNPs that passed the quality control stage were performed on the Michigan Imputation Server 
 
902 (https://imputationserver.sph.umich.edu) using the 1000G Phase3 v5 reference panel54. SNPs 
 
903 previously reported to be associated with postprandial glycemia, triglyceride or insulin GWAS17-20 
 
904 were extracted from the full set of genome wide genotypes using PLINK and tested for association 
 
905 with postprandial measures using linear regression methods. 
 
 
906 Processing of habitual diet information 
907 UK nutrient intakes were determined using FETA software to calculate macro- and micro- nutrient 
 
908 data43. Submitted FFQs were excluded if greater than 10 food items were left unanswered, or if the 
 
909 total energy intake estimate derived from FFQ as a ratio of the subject’s estimated basal metabolic 
 
910 rate (determined by the Harris-Benedict equation)43 was more than two standard deviations outside 
 





913 Statistical analysis 
 
914 Basic analyses 
915 The descriptive characteristics of study participants are summarized in Supplemental Table 1 
 
916 In order to reduce the dimension of the data, principal component analysis (PCAs) with orthogonal 
 
917 transformation (varimax procedure) was applied to derive principal components (PC) representative 
 
918 of individual characteristics (20 PCAs), microbiome (40 PCAs), meal composition (1 PCA), habitual 
 
919 diet (5 PCAs) and meal context (5 PCAs) (see Supplemental Table 3 for full list of input variables). All 
 
920 the necessary prerequisites of PC analysis including linearity, Kaiser–Meyer–Olkin measure of 0.88, 
 
921 and the significant Bartlett’s test of sphericity (p < 0.001) were met. Each participant received a 
 
922 score for each category mentioned above. To investigate the association between each outcome 
 
923 (iAUC, triglyceride6h-rise, C-peptide1h-rise) and our exposures (individual baseline characteristics, 
 
924 microbiome (16S), meal content, habitual diet and meal context) multivariable regressions were 
925 applied and R2 reported. Further, we derived PCAs for the anthropometrics, biochemical/clinical 
926 factors, physical activity and sleep features separately to investigate their role. Multi-collinearity for 
 
927 the multiple linear regressions was assessed with variance inflation factors (VIF) at each step55. 
 
928 Multi-collinearity was considered high when the VIF was >1038. Receiver operating characteristic 
 
929 (ROC) curves were constructed and the area under the curve (AUC) was calculated to assess the 
 
930 discriminatory power of (fasting blood glucose vs. 2h glucose iAUC), (fasting triglyceride vs. 
 
931 triglyceride6h-rise) and (fasting C-peptide vs. C-peptide1h-rise) to detect impaired glucose tolerance, and 
 
932 ASCVD 10 year risk (70% applied as a cut-off point). Values of AUC range from 0.5 and 1, with 0.5 
 
933 indicating no discrimination, and 1 indicating perfect discrimination (2). A p-value ⩽0.05 was 
 





936 Meal composition 
937 To estimate macronutrient effects on glycemic response, we fitted a multivariate regression model 
 
938 with carbohydrates, fats, fiber and protein as predictors on meals 1, 2, 4, 5, 6, 7 and 8. 
37  
939 Multicollinearity was assessed for these predictors through VIF and we concluded that it was non 
 
940 existent (VIF < 10). The regression coefficients were all significant (p < 0.001) with values -79.23 
 
941 mmol/L*s, -142.41 mmol/L*s and -185.49 mmol/L*s for fat, fiber and protein respectively, after 
 
942 having adjusted by carbohydrates. 
 
 
943 Heritability and ACE model 
944 To estimate the heritability, we analyzed the data according to the classical ACE model. In this 
 
945 model, heritability is an approximation of the relative importance of additive genetic differences for 
 
946 variance of postprandial responses in the population56. Shared or familial environmental influences 
 
947 reflect experiences that contribute to twin similarity. Non-shared or individual-specific 
 
948 environmental influences refer to the contribution of environmental experiences not shared by 
 
949 family members. Information concerning shared genetic and environmental influences is best 
 
950 estimated by structural equation modelling techniques that fit models of twins by zygosity in order 
 
951 to describe the 154 causes of the variance in OA. Therefore, the total variance in the trait can be 
 
952 partitioned into genetic variance (A), shared (familial) environmental variance (C), and individual- 
 
953 specific environmental variance (E). The level of statistical significance was set at p<0.05 in all 
 





package (https://rdrr.io/cran/mets/src/R/methodstwinlm.R) was used for all statistical analyses. 
 
 
957 Meal ranking 
958 Six different type of meals were ranked for each individual as being the one with the highest glucose 
 
959 2h iAUC for that person (rank 6), the one with the second highest glucose iAUC (rank 5). .... down the 
 
960 the one with the lowest glucose 2h iAUC (rank 1). The distribution of these “in-person rankings” is 
 





963 Multilinear ANOVA to assess role of individualized responses to meals 
964 The different sources of variation in glycemic response for Meal 2,3,4,6 and 8 (described in 
 
965 Supplemental Table 3) were analysed using the Multilevel Linear ANOVA40   model 
 
966 and were analysed using a multilevel (hierarchical) linear Bayesian ANOVA model as described by 
 
967 Gelman and Hill57. 
 
968 The different sources of variation in glycemic response for Meal 2,3,4,6 and were analysed using a 
 
969 multilevel (hierarchical) Linear Bayesian ANOVA model as described by (Gelman & Hill 2007). 
970 
971 Hierarchical Bayes models can accommodate non-normal dependent variables that are difficult to 
 
972 incorporate in classical ANOVA and multilevel linear models . The approach consists of sub-models at 
 
973 two levels: at level 1 the parameters of individuals, meals and person-meal interactions, and at level 
 
974 2 the moments of the distributions from which level 1 parameters are drawn. Level 2 imposes some 
 
975 homogeneity on level 1 parameters, for example 
976 
977 am ～ N(0, aa2) i.e. the meal terms are are distributed normally with the same standard deviation 
 
978 aa , ensuring homogeneity. 
 
979 aa ～ HalfCauchy(5) i.e. the standard deviation of the above distribution has a particular prior (a 
 
980 half cauchy distribution with a scale factor of 5) - 
 
981 The other terms ({3p , ym,p , Em,p,k , E m,p,k,n) have similar hierarchical distributions (though the 
982 standard deviations of Em,p,k , E m,p,k,n have uniform prior as opposed to a half cauchy). 
983 The parameters at both levels (i.e. all the am ’s and aa and analogously for the other parameters) 
984 are sampled using an Markov Chain Monte-Carlo routine in pymc3 58 and we plot the sampled values 






988 -log(iAUC) =ym,p,k,n: the 2 hour iAUC for person p, eating meal m , for the k th time measured on 
989 cgm n (given the availability of data with 2 CGMs for a subset as described in below. 
990 the 2 hour iAUC for person p, eating meal m , for the k th time measured on cgm n (given that we 
991 have 2 cgms for many people) 
 
992 - am : meal content (across all people) for meal m, e.g. high and low carbohydrate meals 
 
993 - {3p : individual glucose scaling (across all meals) for person p, e.g. overall high and low responding 
994 people 
 
995 - ym,p : the meal-specific response for individual p to meal m, e.g. a specific person responds 
996 particularly strongly to a specific meal 
 
997 - E m,p,k,n : error stemming from the cgm (participants selected for this analysis wore 2 CGM devices, 
998 so n indexes the device providing the measurement) 
 




This Bayesian ANOVA model is a Bayesian hierarchical model attempts to explain the observed 
1001 log(iAUC) of a meal as a sum of categorical terms., i.e. individuals are not classified according to any 
1002 characteristics but are included as unique individuals with log(iAUC 2h glucose) for various different 
1003 meals. If this was an extended Glycemic Index model it would correspond to expressing the 
1004 log(iAUC) as the sum of a meal term (analogous to the glycemic load of the meal) and an 
1005 individualized term. This “individual glucose scaling” is not a linear function of a person’s 
1006 characteristics (such as age, sex or BMI) but rather it is how each individual ranks overall given the 
1007 log(iAUC) values for the various meals. This allowed us to test whether there was an interaction term 
1008 between meals and persons, i.e. an individualized response component to particular meals that was 
1009 not merely due to a person being a high, average or low responder and to a meal having on average 
1010 a higher glycemic response (e.g. OGTT) than another meal (e.g. a high fat muffin). Given the 
40  
1011 availability of data concerning repeated occurrences of a person eating a particular meal and 
 
1012 multiple CGMs measurements for the same meal we were able to extend the model to include a 
 
1013 person-meal interaction and a CGM error and, analogously, infer the error due to the CGMs and the 
 
1014 degree to which a person’s response to a particular meal is consistently higher or lower than one 
 
1015 would expect from the glycemic index model .i.e. a personalized glycemic load. The person-meal 
 
1016 interaction effects allow different people to have different ordering of glycemic responses to meals, 
 
1017 so one person might respond more strongly to meal A than meal B, whilst another person might 
 
1018 respond more strongly to meal B than meal A. Figure 6c shows show 50% and 95% intervals on 
 











A subset of participants (n=483) wore two continuous glucose measurement devices simultaneously, 
 
1024 providing duplicate measurements for the meals they consumed and therefore allowing us to 
 
1025 distinguish CGM error from unexplained sources of variation. Postprandial glucose measurements 
 










Computation of clinical indices 
Atherosclerotic Cardiovascular Disease 10 year risk: (AHA/JACC ASCVD 10 year risk) The 10-year 
 
1031 atherosclerotic cardiovascular disease (ASCVD) 59 risk score is a gender and race specific single 
 
1032 multivariable risk assessment tool used to estimate the 10-year CVD risk of an individual, and has 
1033 clinically replaced the Framingham-10 year cardiovascular risk score. It is based on the age, sex, 
1034 ethnicity, total and HDL cholesterol, systolic blood pressure, smoking status, use of blood pressure 
1035 lowering medications, and the presence of type 2 diabetes (T2D). 
41  
1036 Impaired glucose tolerance: We used the standard definition from the American Diabetes 
 










Validation of Machine learning model cross validation and difference (Bland-Altman plots) 
To further illustrate the reliability of the machine learning predictions, we conducted a leave-one- 
 
1042 out cross validation procedure and generated Bland-Altman plots to analyze the agreement 
 
1043 between two. To generate the Bland-Altman plots we used the Predict UK and US data showing 
 
1044 Predicted vs Measured postprandial responses. We generated Bland-Altman plots for predicted and 
 
1045 measured postprandial responses for each biomarker (Triglycerides, C-peptide and Glucose). 
 





Leave-one-out cross-validated Pearson R scores in Predict UK 
To perform k-fold cross validation, the entire dataset is split into k groups. Treating each group as a 
 
1049 test set and the remaining groups as the training set, the model is fitted k times. The Pearsons’s R 
 
1050 between the values predicted by the fitted models and the measured values in the test sets is used 
 
1051 as the metric for model evaluation, which we refer to as the cross-validated Pearson-R. 
1052 
1053 The special case, where k is the size of the dataset, is referred to as leave-one-out cross-validation, 
 
1054 and we refer to the corresponding evaluation metric as leave-one-out cross-validated Pearson R. The 
 
1055 machine learning models for the three biomarkers of interest were evaluated using the 
 
1056 aforementioned metric and are reported in the Extended Data Figure 4b . These scores are similar to 
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Fasting levels AUC =0.55 (0.49-0.61) 
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Extended Data Figure 2. Repeatability in the PREDICT 1 study 
 
a. Intraclass co rrelat io ns 
 
 
Metabolic outcome num meals Timepoint/ traitICC 95%CI 
TG 648 fa st ing 0.670.60 - 0.72 
  Sh 0.660.60 - 0.72 
  6h 0.730.68 - 0.78 
  fasting-Sh rise 0.410.32 - 0.49 
  fasting-6h rise 0.460.37 - 0.54 
 
2lucose 8038 2h-iAUC 0.74 0.72 - 0.75 
 
c-peptide 626 fasting 0.720.66 - 0.77 
  0.Sh 0.560.47 - 0.64 
  2h 0.710.64 - 0.76 
  fasting-0.S h rise 0.470.37 - 0.56 






































b. Pea rso n's co rrela tion and CV of 2h-iAUCs 
measured w it h two monito rs wo rn by the same 
participant (n=377). P-va lue from two -s ide d t- 
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c. Mean and standard error of fastingand postprandia l s e rum insulin and C-peptide co nce ntratio ns during the clinic vis it in the  PREDICT 


























































Extended Data Figure 3. Frequency distribution of in-person ranking for 6 of meals shown in Figure 
6a (High fat 40g = meal 7, High protein = meal 8, UK average= meal 2, High carb = meal 4, OGTT = meal 5, 
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Extended Data Figure 4. Machine Learning comparisons, cross validat ion and repeatabilit y 
 
a. Bland-Alt man plots co mparing predict ed and measured postprandial respo nses in TG, glucose and C-peptide using UK and US dat a. The sample sizesused 
n=number of meals: tri glyceride UK: n=958 US: n=91; C-peptide UK: n=957 US: n=93; Glucose UK:n=l l SSO US : n 1200 
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b. Leave-o ne-o ut cross-validated Pearson R scores in PREDICT UK. 5-fo ld cross vali dat ion for Triglyceride 6 hour rise on n=958 meals, for 
Glucose2h iAUCon n=l l ,550 meals, p-values shown for t wo-sided t-test 
 
 
UK dat a set TG6h·rise 
Lea ve-o ne-o ut 0.49, p = 2.03e -56 
Glucose;Au co-2h 








individual glucose scaling estimat e using all repeat meals : 
18.7%changein glucose2h iAUC95%CI [17.9-19.5 %] 
indivdiual usi ng onlya si nglemeal from each set (one OGTT, one 
high carb, one high fat etc). 
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